Tüdőrák: vizsgálatok itt: Törökország

In Törökország 82 Also abroad 2746

82 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.

3. fázisTaking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Adana, Adapazarı, Ankara, Antalya, Edirne, Gaziantep, Istanbul, Izmir, Pendik, Samsun
Életkor
18 év and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
3. fázisTaking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Adana, Ankara, Bornova, Denizli, Istanbul, Samsun, Stanbul, Talas
Életkor
18 év and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
2. fázisTaking people
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Where
Istanbul, Sakarya
Életkor
18 év and over
People
130 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00
1/2. fázisTaking people
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Where
Ankara, Çankaya, Istanbul
Életkor
18 év and over
People
60 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07227025
2/3. fázisTaking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Adana, Ankara, Antalya, Diyarbakır, Gaziantep, Istanbul, Izmir, Kadıköy, Keçiören, Kocaeli, Konya, Küçükçekmece, Ordu, Ortahisar, Sakarya, Samsun, Seyhan, Toroslar, Yenimahalle, Zeytinburnu
Életkor
18 év and over
People
1580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
3. fázisTaking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Ankara, Antalya, Istanbul
Életkor
18 év and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
3. fázisTaking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Adana, Ankara, Istanbul, Türkiye
Életkor
18 év and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
2/3. fázisTaking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Alanya, Altındağ, Ankara, Antalya, Atakum, Bahçelievler, Bornova, Çankaya, Edirne, Fatih, Gaziantep, Istanbul, Izmir, Kadıköy, Kocaeli, Malatya, Mamak, Şişli
Életkor
18 év and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
3. fázisTaking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Adana, Ankara, Battalgazi/malatya, Bursa, Çankaya, Cordaleo, Diyarbakır, Istanbul, Izmir
Életkor
18 év and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
3. fázisTaking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Ankara, Izmir, Kayseri, Mersin, Samsun, Stanbul
Életkor
18 év and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Ankara, Antalya, Istanbul, Yenimahalle
Életkor
18 év and over
People
1160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
3. fázisTaking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Adapazarı, Ankara, Antalya, Diyarbakır, Istanbul
Életkor
18 év and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Ankara, Antalya, Edirne, Izmir, Seyhan
Életkor
18 év and over
People
1160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
1/2. fázisTaking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Ankara, Fatih, Istanbul
Életkor
18 év and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
1/2. fázisTaking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Adana, Adapazarı, Ankara, Denizli, Istanbul, Konya, Samsun
Életkor
18 év and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
3. fázisTaking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Adana, Ankara, Istanbul, Izmir, Izmir, Karsiyaka
Életkor
18 év and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
2. fázisTaking people
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Where
Adana, Ankara, Istanbul
Életkor
18 év and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00
3. fázisTaking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Adana, Ankara, Istanbul
Életkor
18 év and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
3. fázisNot yet taking people in Törökország
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Adana, Ankara, Antalya, Çankaya, Cordaleo, Istanbul, Izmir
Életkor
18 év and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
2. fázisTaking people
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Where
Ankara, Istanbul, Izmir
Életkor
18 év to 95 év
People
630 worldwide
Run by
AstraZeneca
See details and how to joinNCT05061550 · EU 2023-508852-21-00
2. fázisTaking people
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Where
Adana, Ankara
Életkor
18 év and over
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06731907 · EU 2024-515772-12-00
3. fázisTaking people
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Where
Adana, Ankara, Çankaya, Fatih, Istanbul, Kadıköy, Sakarya
Életkor
18 év and over
People
480 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146
3. fázisTaking people
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Where
Adana, Ankara, Antalya, Edirne, Istanbul, Izmir, Kocaeli, Mamak, Sakarya
Életkor
18 év and over
People
621 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00
3. fázisNot yet taking people in Törökország
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Where
Adana, Ankara, Atakum, Bahçelievler, Edirne, Esenyurt, Etlik, Gaziantep, Istanbul, Izmir, Küçükçekmece, Şehitkamil, Sur, Turgutlu, Yüreğir
Életkor
18 év and over
People
360 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00
1/2. fázisTaking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Ankara, Istanbul, Yüreğir
Életkor
18 év and over
People
1438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00